Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors

[1]  D. Neuberg,et al.  Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. , 2016, JAMA oncology.

[2]  U. Pastorino,et al.  Conversion to stem‐cell state in response to microenvironmental cues is regulated by balance between epithelial and mesenchymal features in lung cancer cells , 2015, Molecular oncology.

[3]  F. Grillo,et al.  Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible? , 2016, Endocrine.

[4]  R. Fiocca,et al.  Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor , 2015, Neuroendocrinology.

[5]  W. Dinjens,et al.  Succinate Dehydrogenase (SDH)-Deficient Pancreatic Neuroendocrine Tumor Expands the SDH-Related Tumor Spectrum. , 2015, The Journal of clinical endocrinology and metabolism.

[6]  A. Gill,et al.  Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas. , 2015, Human pathology.

[7]  P. Ferrari,et al.  Cellular Plasticity, Cancer Stem Cells and Metastasis , 2015 .

[8]  H. Falhammar,et al.  Ileal neuroendocrine tumors and heart: not only valvular consequences , 2015, Endocrine.

[9]  C. Stratakis,et al.  The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations , 2014, Endocrine.

[10]  W. ElShamy,et al.  Overview: cellular plasticity, cancer stem cells and metastasis. , 2013, Cancer letters.

[11]  V. Mazzaferro,et al.  Succinate Dehydrogenase B Subunit Immunohistochemical Expression Predicts Aggressiveness in Well Differentiated Neuroendocrine Tumors of the Ileum , 2012, Cancers.

[12]  I. Tomlinson,et al.  SDH mutations in cancer. , 2011, Biochimica et biophysica acta.

[13]  B. Niederle,et al.  Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. , 2010, Endocrine-related cancer.

[14]  A. Chou,et al.  Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. , 2010, Human pathology.

[15]  A. Chou,et al.  Immunohistochemistry for SDHB Divides Gastrointestinal Stromal Tumors (GISTs) into 2 Distinct Types , 2010, The American journal of surgical pathology.

[16]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  B. Kos-Kudła,et al.  Poorly-Differentiated Endocrine Carcinomas of Midgut and Hindgut Origin , 2007, Neuroendocrinology.

[18]  E. Baudin,et al.  Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. , 2007, The Journal of clinical endocrinology and metabolism.

[19]  F. Keleştimur,et al.  Poorly Differentiated Carcinomas of the Foregut (Gastric, Duodenal and Pancreatic) , 2007, Neuroendocrinology.

[20]  N. Lemoine,et al.  Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. , 2006, Endocrine-related cancer.

[21]  I. Modlin,et al.  Therapeutic options for gastrointestinal carcinoids. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.